Incysus is focused on delivering a novel cell therapy for the treatment of cancer. By using genetically modified gamma-delta (γδ) T cells, the Company’s technology addresses the challenges that immunotherapies face targeting cold, low mutation cancers. Incysus’ immuno-oncology programs include activated and gene-modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells. Since the Company’s inception in early 2016, Incysus has received approval of two Investigational New Drug applications (IND) and has initiated several cancer programs in early pre-clinical stages, including a checkpoint combination program. The Company’s first program is targeted to leukemia and its second program is targeted to the treatment of newly-diagnosed glioblastoma (GBM). In collaboration with our academic partners, Incysus has advanced its technology into initial Phase I trials.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Drug Resistant Immunotherapy
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):